- Sector(s): Healthcare
- Industry: Drug Manufacturers—Specialty & Generic
- Full Time Employees: 28
- Founded in 2007
- Headquartered in Devon, Pennsylvania
- http://zynerba.com
Zynerba Pharma announces 'positive' top line results from an open label exploratory Phase 2 FAB-C clinical trial evaluating ZYN002 cannabidiol (CBD) gel in pediatric and adolescent patients with Fragile X syndrome
ZYN002 successfully met the primary endpoint and showed clinically 'meaningful improvements'
- ZYN002 also achieved clinically meaningful improvements in all measures of the Aberrant Behavior Checklist for Fragile X (ABC-FXS), which address the key symptoms of FXS including social avoidance, temper tantrums, repetitive movements, and hyperactivity.
- "The data from the FAB-C trial are very exciting and demonstrate that ZYN002 may have a profound effect on improving many of the most disabling symptoms of Fragile X, such as anxiety and difficult behaviors."
- With these data, Zynerba anticipates that it will meet with the FDA in the first half of 2018 with the goal of moving quickly into a pivotal Phase 2/3 program in pediatric and adolescent patients with FXS in 2018.
** charts before **
No comments:
Post a Comment